Clinical-stage biopharma developing an oral PDPN-targeting cancer therapeutic (MASL / lenipagrusin alfa) that blocks podoplanin to inhibit tumor growth, invasion, immune evasion and resistance and triggers necrotic tumor cell death. Aimed at cancers with elevated PDPN—initial clinical studies focus on head and neck cancer; early human trials show tolerability and potential benefit as monotherapy and with standard-of-care.